Cargando…

Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy

BACKGROUND: Surveillance after orchiectomy has recently been a management option in patients with stage I seminoma, while it remains controversial in those with stage I nonseminoma, and the risk factor associated with relapse is still a matter of concern in both entities. This study was performed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Kazuhiro, Saito, Toshihiro, Kitamura, Yasuo, Nobushita, Tomohiro, Kawasaki, Takashi, Hara, Noboru, Takahashi, Kota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632495/
https://www.ncbi.nlm.nih.gov/pubmed/23566361
http://dx.doi.org/10.1186/1746-1596-8-57
_version_ 1782266866641666048
author Kobayashi, Kazuhiro
Saito, Toshihiro
Kitamura, Yasuo
Nobushita, Tomohiro
Kawasaki, Takashi
Hara, Noboru
Takahashi, Kota
author_facet Kobayashi, Kazuhiro
Saito, Toshihiro
Kitamura, Yasuo
Nobushita, Tomohiro
Kawasaki, Takashi
Hara, Noboru
Takahashi, Kota
author_sort Kobayashi, Kazuhiro
collection PubMed
description BACKGROUND: Surveillance after orchiectomy has recently been a management option in patients with stage I seminoma, while it remains controversial in those with stage I nonseminoma, and the risk factor associated with relapse is still a matter of concern in both entities. This study was performed to explore pathological risk factors for post-orchiectomy relapse in patients with stage I seminoma and nonseminoma, and to assess oncological outcomes in those managed with surveillance. METHODS: In this single institution study, 118 and 40 consecutive patients with stage I seminoma and nonseminoma were reviewed, respectively. Of the 118 patients with stage I seminoma, 56 and one received adjuvant radiotherapy and chemotherapy, respectively, and 61 were managed with surveillance. Of the 40 men with stage I nonseminoma, 4 underwent adjuvant chemotherapy and 36 were managed with surveillance. RESULTS: No patient had cause-specific death during the mean observation period of 104 and 99 months in men with seminoma and nonseminoma, respectively. In men with stage I seminoma, 1 (1.7%) receiving radiotherapy and 4 (6.6%) men managed with surveillance had disease relapse; the 10-year relapse-free survival (RFS) rate was 93.4% in men managed with surveillance, and their RFS was not different from that in patients receiving adjuvant radiotherapy (logrank P=0.15). Patients with tunica albuginea involvement showed a poorer RFS than those without (10-year RFS rate 80.0% vs. 94.1%), although the difference was of borderline significance (P=0.09). In men with stage I nonseminoma, 9 (22.5%) patients experienced relapse. Patients with lymphovascular invasion seemingly had a poorer RFS than those without; 40.0% and 18.7% of the patients with and without lymphovascular invasion had disease relapse, respectively, although the difference was not significant (logrank P=0.17). CONCLUSION: In both men with stage I seminoma and nonseminoma, surveillance after orchiectomy is a feasible option. However, disease extension through tunica albuginea might be a factor associated with disease relapse in patients with organ-confined seminoma, and those with stage I nonseminoma showing lymphovascular invasion may possibly be at high risk for disease relapse.
format Online
Article
Text
id pubmed-3632495
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36324952013-04-23 Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy Kobayashi, Kazuhiro Saito, Toshihiro Kitamura, Yasuo Nobushita, Tomohiro Kawasaki, Takashi Hara, Noboru Takahashi, Kota Diagn Pathol Research BACKGROUND: Surveillance after orchiectomy has recently been a management option in patients with stage I seminoma, while it remains controversial in those with stage I nonseminoma, and the risk factor associated with relapse is still a matter of concern in both entities. This study was performed to explore pathological risk factors for post-orchiectomy relapse in patients with stage I seminoma and nonseminoma, and to assess oncological outcomes in those managed with surveillance. METHODS: In this single institution study, 118 and 40 consecutive patients with stage I seminoma and nonseminoma were reviewed, respectively. Of the 118 patients with stage I seminoma, 56 and one received adjuvant radiotherapy and chemotherapy, respectively, and 61 were managed with surveillance. Of the 40 men with stage I nonseminoma, 4 underwent adjuvant chemotherapy and 36 were managed with surveillance. RESULTS: No patient had cause-specific death during the mean observation period of 104 and 99 months in men with seminoma and nonseminoma, respectively. In men with stage I seminoma, 1 (1.7%) receiving radiotherapy and 4 (6.6%) men managed with surveillance had disease relapse; the 10-year relapse-free survival (RFS) rate was 93.4% in men managed with surveillance, and their RFS was not different from that in patients receiving adjuvant radiotherapy (logrank P=0.15). Patients with tunica albuginea involvement showed a poorer RFS than those without (10-year RFS rate 80.0% vs. 94.1%), although the difference was of borderline significance (P=0.09). In men with stage I nonseminoma, 9 (22.5%) patients experienced relapse. Patients with lymphovascular invasion seemingly had a poorer RFS than those without; 40.0% and 18.7% of the patients with and without lymphovascular invasion had disease relapse, respectively, although the difference was not significant (logrank P=0.17). CONCLUSION: In both men with stage I seminoma and nonseminoma, surveillance after orchiectomy is a feasible option. However, disease extension through tunica albuginea might be a factor associated with disease relapse in patients with organ-confined seminoma, and those with stage I nonseminoma showing lymphovascular invasion may possibly be at high risk for disease relapse. BioMed Central 2013-04-08 /pmc/articles/PMC3632495/ /pubmed/23566361 http://dx.doi.org/10.1186/1746-1596-8-57 Text en Copyright © 2013 Kobayashi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kobayashi, Kazuhiro
Saito, Toshihiro
Kitamura, Yasuo
Nobushita, Tomohiro
Kawasaki, Takashi
Hara, Noboru
Takahashi, Kota
Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy
title Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy
title_full Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy
title_fullStr Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy
title_full_unstemmed Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy
title_short Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy
title_sort oncological outcomes in patients with stage i testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632495/
https://www.ncbi.nlm.nih.gov/pubmed/23566361
http://dx.doi.org/10.1186/1746-1596-8-57
work_keys_str_mv AT kobayashikazuhiro oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy
AT saitotoshihiro oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy
AT kitamurayasuo oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy
AT nobushitatomohiro oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy
AT kawasakitakashi oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy
AT haranoboru oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy
AT takahashikota oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy